Physician profile
Brian D Brightman
NPI 1407876600
$16,488.00
in general payments reported to CMS, 2019-2025
18 companies · $2,391 in 2025
The $2,391 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,538 · 2020: $2,650 · 2021: $3,455 · 2022: $869 · 2023: $974 · 2024: $612 · 2025: $2,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Consulting Fee: $980 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.25 |
| Consulting Fee | $980.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,839.69 | 2019-2022 | |
| Coopervision INC. | $1,109.71 | 2020-2025 | Proclear Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $851.53 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $811.23 | 2019-2025 | Precision7, Total30, Precision 7 |
| Johnson & Johnson Vision Care, INC. | $790.74 | 2020-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $649.87 | 2020-2025 | Cequa |
| Oyster Point Pharma, INC. | $380.40 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $227.45 | 2022-2025 | Oxervate |
| Glaukos Corporation | $193.45 | 2025 | Photrexa Viscous and Photrexa |
| Horizon Therapeutics Plc | $175.96 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $97.27 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $95.52 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $79.90 | 2021 | |
| Abbvie INC. | $78.35 | 2022-2023 | Lumigan, Alphagan P |
| Rxsight INC | $42.45 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.38 | 2020-2021 | |
| Shire North American Group INC | $16.12 | 2019 | |
| Sight Sciences, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Brightman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.